Natera, Inc. - Common Stock (NTRA)

Natera's new CEO outlines a path to double revenue by 2029

Natera (NASDAQ:NTRA) raised its full-year revenue forecast after reporting a 34% increase in third-quarter revenue, as demand for its cancer-monitoring tests grew and the company announced a change in leadership. Steve Chapman is stepping down as chief executive officer and handing the role to Solo

Genetic testing company Natera (NASDAQ:NTRA) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 34.1% year on year to $794 mi...

Genetic testing company Natera (NASDAQ:NTRA) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 34.1% year on year to $794...

Genetic testing company Natera (NASDAQ:NTRA) will be announcing earnings results this Thursday after the bell. Here’s what to expect. Natera beat analysts’ r...

The business is promising, but the valuation today has gone to the stratosphere.

What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA) jumped 2.4% in the afternoon session after the company announced that incorporating pha...

What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA) jumped 1.7% in the morning session after the U.S. Food and Drug Administration granted ...

Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca...

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...

Check out the companies making headlines yesterday: AutoZone (NYSE:AZO): Auto parts and accessories retailer AutoZone (NYSE:AZO) rose by 6.1% on Tuesday afte...

What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA) jumped 5.2% in the afternoon session after the company announced that Japan's Pharmaceu...

The sale was executed under a pre-arranged Rule 10b5-1 plan amended in March 2026, leaving Chapman with 98,199 directly held shares.

The well-respected investor has Meta Platforms, Delta Air Lines, and Eli Lilly in his family office's portfolio. The stock isn't one of those.

What a time it’s been for Natera. In the past six months alone, the company’s stock price has increased by a massive 59.9%, reaching $328.13 per share. This ...

His largest position today is a bet on genomics.

Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 27.54% on an annualized basis producing an average annual return of 40.97%. Currently, Natera has a market capitalization of $47.31 billion.

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u...

The billionaire has good reasons to like this genetic testing leader.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...

Duquesne Family Office has beefed up its healthcare holdings.